Trademark: 79087263
Status Date
Friday, June 19, 2020
Registration Number
3922327
Registration Date
Tuesday, February 22, 2011
Filing Date
Saturday, June 19, 2010
Published for Opposition
Tuesday, December 7, 2010
Cancellation Date
Friday, June 19, 2020
5 Pharmaceuticals for use in stimulating human blood cell production; pharmaceuticals for the treatment of cancer, anemia, ischemia, myocardial infarction, congestive heart failure, renal failure, anoxia-induced cellular degeneration, hypoxia-induced cellular degeneration and stroke
Jul 10, 2021
Notification Of Effect Of Cancellation Of Intl Reg E-Mailed
Jul 10, 2021
Death Of International Registration
Sep 14, 2018
Total Invalidation Processed By The Ib
Jun 4, 2018
Total Invalidation Of Reg Ext Protection Sent To Ib
Jun 4, 2018
Invalidation Processed
May 29, 2018
Total Invalidation Of Reg Ext Protection Created
Sep 29, 2017
Cancelled Section 71
Aug 4, 2016
New Representative At Ib Received
Feb 22, 2016
Courtesy Reminder - Sec. 71 (6-Yr) E-Mailed
Oct 11, 2013
Teas Change Of Correspondence Received
May 25, 2011
Notification Processed By Ib
Apr 27, 2011
Final Disposition Notice Sent To Ib
Apr 27, 2011
Final Disposition Processed
Mar 24, 2011
Grant Of Protection Created, To Be Sent To Ib
Feb 22, 2011
Registered-Principal Register
Dec 7, 2010
Published For Opposition
Dec 2, 2010
Attorney/Dom.Rep.Revoked And/Or Appointed
Dec 2, 2010
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Nov 17, 2010
Notice Of Publication
Nov 3, 2010
Law Office Publication Review Completed
Nov 3, 2010
Assigned To Lie
Oct 20, 2010
Approved For Pub - Principal Register
Oct 19, 2010
Application Filing Receipt Mailed
Oct 15, 2010
Assigned To Examiner
Oct 15, 2010
New Application Office Supplied Data Entered In Tram
Oct 14, 2010
Sn Assigned For Sect 66a Appl From Ib
Trademark Alertz updated from USPTO on 2030-01-24
